Humira
Skyrizi Surpasses Humira as AbbVie’s Top-Selling Drug
Skyrizi, Humira, AbbVie, revenue leader, immunology, plaque psoriasis, psoriatic arthritis, Crohn’s disease
Cigna’s Express Scripts to Remove Humira from Preferred Lists in Favor of Cheaper Biosimilars
Cigna, Express Scripts, Humira, biosimilars, drug pricing, pharmaceutical industry
Cigna’s Evernorth Pushes for Increased Humira Biosimilar Adoption
Cigna, Evernorth, Humira, biosimilars, healthcare, pharmacy services, cost savings, patient access, AbbVie
AbbVie’s Rinvoq Leads Immunology Market as Physicians Rank Players, J&J Sees Decline
AbbVie, Rinvoq, Immunology players, Physicians’ ranking, J&J drop, Humira, Crohn’s disease, FDA approval, JAK inhibitor
AbbVie Acquires Landos Biopharma to Enhance Post-Humira Immunology Pipeline
AbbVie, Landos Biopharma, Small acquisition, IBD (Inflammatory Bowel Disease) drug, Humira, Autoimmune startup, Immunology pipeline